[{"Assets_0_Q3_USD":11842600000.0,"CommonStockDividendsPerShareDeclared_1_Q3_USD":0.16,"CommonStockDividendsPerShareDeclared_3_Q3_USD":0.48,"CommonStockSharesOutstanding_0_Q3_shares":140800000.0,"EarningsPerShareBasic_1_Q3_USD":0.31,"EarningsPerShareBasic_3_Q3_USD":0.33,"EarningsPerShareDiluted_1_Q3_USD":0.31,"EarningsPerShareDiluted_3_Q3_USD":0.32,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":482000000.0,"NetIncomeLoss_1_Q3_USD":44500000.0,"NetIncomeLoss_3_Q3_USD":46400000.0,"StockholdersEquity_0_Q3_USD":6041700000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":141700000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":142800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":141300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":142500000.0,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20171109"}]